Eur Rev Med Pharmacol Sci 2019; 23 (15): 6579-6587

DOI: 10.26355/eurrev_201908_18544

Sevoflurane inhibits the progression of PTC by downregulating miR-155

Y. Li, Q.-G. Zeng, J.-L. Qiu, T. Pang, H. Wang, X.-X. Zhang

Department of Thyroid and Breast Surgery, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong. zhxuex@sysu.edu.cn


OBJECTIVE: Surgery resection is the primary treatment for papillary thyroid carcinoma (PTC) patients with the risk of tumor cell invasion and distant metastasis. Sevoflurane is a volatile anesthetic agent widely used in clinical applications. However, the effect of sevoflurane on PTC cells and its precise mechanism remain largely unknown.
MATERIALS AND METHODS: Cell viability was assessed by MTT assay. The migrative and invasive abilities of the cells were measured by transwell assay. The protein expression level of Bax, Bcl-2, MMP 9, and MMP 2 were detected by Western blot. Cell apoptosis was analyzed by flow cytometry. The qRT-PCR analysis was used to determine miR-155 expressions.
RESULTS: Sevoflurane greatly decreased the viability of PTC cells in a dose-dependent manner. Moreover, sevoflurane significantly inhibited migration and invasion, but increased the apoptosis in PTC cells, which could be reversed by the addition of miR-155. Besides, sevoflurane evidently increased the Bax protein level and inhibited the protein level of Bcl-2, MMP9, and MPP2 in PTC cells. In addition, miR-155 was upregulated in PTC cells; however, the amount of miR-155 would be decreased in PTC cells treated with sevoflurane. Furthermore, abrogation of miR-155 promoted cell apoptosis and inhibited cell migration and invasion in PTC cells.
CONCLUSIONS: Sevoflurane inhibited migration and invasion, while enhanced cell apoptosis by downregulating miR-155 in PTC cells, suggesting important clinical implications for anesthetic agents to prevent the metastasis in PTC.

Free PDF Download

To cite this article

Y. Li, Q.-G. Zeng, J.-L. Qiu, T. Pang, H. Wang, X.-X. Zhang
Sevoflurane inhibits the progression of PTC by downregulating miR-155

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 15
Pages: 6579-6587
DOI: 10.26355/eurrev_201908_18544